Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CeTeG, 2009-011252-22, NCT01149109

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NOA-07, NCT01614132

Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 30 at initial diagnosis
Sponsor: Other
Protocol IDs: CHP-693, CHP-IRB-2001-12-2301, NCI-V01-1680, NCT00031590

Phase: Phase II
Type: Treatment
Status: Active
Age: 3 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000288826, MSKCC-02088, NCT00058370

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GFPC 05-01, NCT00418743

Phase: Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: 00591, Eudract: 2008-007645-31, NCT00989352

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-0597, NCT01067469

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000694627, EORTC-26101, EU-21103, EUDRACT-2010-023218-30, ROCHE-EORTC-26101, NCT01290939

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13849, H9H-MC-JBAL, NCT01582269

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: DepoRaCe, NCT01563614

Phase: No phase specified
Type: Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: GPOH-HIT-2000, EU-205105, NCT00303810